Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
(Thomson Reuters ONE) -
Curetis /
Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
- Dr. Nils Clausnitzer elected as member of the Supervisory Board
Amsterdam, the Netherlands, and Holzgerlingen, Germany, June 23, 2017 -- Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today reported the results of its
Annual Shareholder Meeting ("AGM") held in Amsterdam on June 23, 2017.
The shareholders approved all items on the agenda of the AGM, including the
election of Dr. Nils Clausnitzer (Senior Vice President and President EMEA-APAC
Lab and Distribution Services of VWR International llc./ VWR GmbH, Germany) as a
member of Curetis' Supervisory Board for a three-year term until 2020. Nils
Clausnitzer has profound knowledge in sales and marketing of diagnostics and
medical products. Prior to VWR International, he was President and Head of
Commercial Operations, EMEA at Qiagen N.V. and General Manager for Olympus
Germany. He also worked as Managing Director for Abbott Diagnostics Germany.
Moreover, Dr. Holger Reithinger and Dr. Rudy Dekeyser were re-elected for
another one-year term, respectively. In addition, the proposed extension of
authorization of the Management Board to limit or exclude pre-emptive rights on
newly issued shares or rights to subscribe for shares as well as an extension of
authorization of the Management Board to repurchase shares were also approved by
the shareholders.
"We are excited to have Nils Clausnitzer on our board," said Oliver Schacht, CEO
of Curetis. "He brings unparalleled expertise in the commercialization of
molecular diagnostics and medical products and deep market knowledge coupled
with his medical background to Curetis. Nils Clausnitzer will play a key role in
helping Curetis drive its commercial rollout. Moreover, we are pleased that all
proposed AGM resolutions have been approved with big majorities by our
shareholders."
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies,
and has entered into several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of
Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D
and related scientific and business opportunities of the GEAR assets acquired in
2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Tel. +49 30 23 63 27 68
Curetis_Logo:
http://hugin.info/171382/R/2115389/804956.jpg
20170623_Curetis_PR_EN_AGM 2017 results:
http://hugin.info/171382/R/2115389/804955.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.06.2017 - 17:34 Uhr
Sprache: Deutsch
News-ID 549580
Anzahl Zeichen: 7315
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
